Quadrant Capital Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-91
| Closed | -$3.66K | – | 1325 |
|
|
2026
Q1 | $3.66K | Sell |
91
-734
| -89% | -$15.8K | ﹤0.01% | 2415 |
|
|
2025
Q4 | $20.7K | Buy |
825
+656
| +388% | +$15.4K | ﹤0.01% | 1977 |
|
|
2025
Q3 | $3.83K | Buy |
+169
| New | +$3.94K | ﹤0.01% | 2367 |
|
|
2025
Q1 | – | Sell |
-261
| Closed | -$8.33K | – | 2749 |
|
|
2024
Q4 | $8.33K | Buy |
261
+222
| +569% | +$6.68K | ﹤0.01% | 2182 |
|
|
2024
Q3 | $1.13K | Sell |
39
-103
| -73% | -$3.81K | ﹤0.01% | 2577 |
|
|
2024
Q2 | $5.45K | Sell |
142
-38
| -21% | -$1.72K | ﹤0.01% | 2273 |
|
|
2024
Q1 | $10.6K | Buy |
180
+6
| +3% | +$382 | ﹤0.01% | 2083 |
|
|
2023
Q4 | $10.4K | Sell |
174
-33
| -16% | -$1.67K | ﹤0.01% | 2053 |
|
|
2023
Q3 | $7.88K | Buy |
207
+84
| +68% | +$3.69K | ﹤0.01% | 2050 |
|
|
2023
Q2 | $11.2K | Hold |
123
| – | – | ﹤0.01% | 1952 |
|
|
2023
Q1 | $8.11K | Buy |
+123
| New | +$7.1K | ﹤0.01% | 2110 |
|
|
2022
Q3 | – | Sell |
-84
| Closed | -$4K | – | 2630 |
|
|
2022
Q2 | $4K | Buy |
+84
| New | +$3.83K | ﹤0.01% | 2013 |
|
|
2021
Q4 | – | Sell |
-8
| Closed | – | – | 2496 |
|
|
2021
Q3 | $0 | Buy |
+8
| New | +$449 | ﹤0.01% | 2492 |
|
Other funds holding APLS
Quadrant Capital Group's APLS Position: Q2 2026 in Review
Quadrant Capital Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 91 shares — an estimated $3.66K sold.
Quadrant Capital Group first reported a position in APLS in Q3 2021 and held it in 13 quarters. The position peaked at $20.7K in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Quadrant Capital Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Quadrant Capital Group sold 91 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.66K.
- Quadrant Capital Group first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 13 quarters.
- Quadrant Capital Group's Apellis Pharmaceuticals position peaked at $20.7K in Q4 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.